DiaMedica Therapeutics Inc. operates primarily in the United States and Canada, advancing its proprietary pipeline of protein-based therapeutics. The company's flagship product candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, designed to promote neuroprotection and tissue repair. DiaMedica is currently evaluating DM199 in clinical trials for the treatment of acute ischemic stroke (AIS) and preeclampsia. By modulating the kallikrein-kinin system, the therapy aims to restore blood flow and reduce inflammation in patients with high unmet medical needs. As a clinical-stage entity, the company does not yet generate commercial product revenue and focuses its resources on research, development, and regulatory milestones.
